Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial

Lilly announced positive topline results from TRANSCEND-T2D-2, a Phase 3 head-to-head trial of retatrutide vs injectable Ozempic 2 mg in 1,298 adults with type 2 diabetes. At 80 weeks, both retatrutide doses cut A1C by an average of 2.2% vs 1.8% for Ozempic and produced roughly double the weight loss (44.3 lbs / 19.5% at 9 mg; 47.4 lbs / 20.9% at 12 mg vs 20.9 lbs / 9.4%), meeting the primary and all key secondary endpoints with p<0.001. The most common adverse events were gastrointestinal, with discontinuation rates of 4.8% (9 mg) and 7.9% (12 mg) vs 2.7% for Ozempic. Retatrutide remains investigational and not approved anywhere; detailed results will be published and presented later.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.